Dr. Reddy’s signed a US commercialization agreement granting Fresenius Kabi exclusive rights to market its rituximab biosimilar.
The deal follows FDA clearance for the product, positioning Fresenius Kabi to lead the US launch while Dr. Reddy’s supplies from its Hyderabad biologics site.
RDY•
